Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Arch Toxicol ; 97(9): 2303-2328, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37402810

RESUMO

Genotoxicity data are mainly interpreted in a qualitative way, which typically results in a binary classification of chemical entities. For more than a decade, there has been a discussion about the need for a paradigm shift in this regard. Here, we review current opportunities, challenges and perspectives for a more quantitative approach to genotoxicity assessment. Currently discussed opportunities mainly include the determination of a reference point (e.g., a benchmark dose) from genetic toxicity dose-response data, followed by calculation of a margin of exposure (MOE) or derivation of a health-based guidance value (HBGV). In addition to new opportunities, major challenges emerge with the quantitative interpretation of genotoxicity data. These are mainly rooted in the limited capability of standard in vivo genotoxicity testing methods to detect different types of genetic damage in multiple target tissues and the unknown quantitative relationships between measurable genotoxic effects and the probability of experiencing an adverse health outcome. In addition, with respect to DNA-reactive mutagens, the question arises whether the widely accepted assumption of a non-threshold dose-response relationship is at all compatible with the derivation of a HBGV. Therefore, at present, any quantitative genotoxicity assessment approach remains to be evaluated case-by-case. The quantitative interpretation of in vivo genotoxicity data for prioritization purposes, e.g., in connection with the MOE approach, could be seen as a promising opportunity for routine application. However, additional research is needed to assess whether it is possible to define a genotoxicity-derived MOE that can be considered indicative of a low level of concern. To further advance quantitative genotoxicity assessment, priority should be given to the development of new experimental methods to provide a deeper mechanistic understanding and a more comprehensive basis for the analysis of dose-response relationships.


Assuntos
Dano ao DNA , Mutagênicos , Mutagênicos/toxicidade , Mutagênicos/análise , DNA , Medição de Risco , Testes de Mutagenicidade/métodos
2.
Regul Toxicol Pharmacol ; 90: 95-103, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28822876

RESUMO

With respect to hazard classification for developmental toxicity under the CLP Regulation it is important to consider the possible influence of maternal toxicity. The aim of the present review was to characterize to which extent developmental effects could be caused by non-specific maternal toxicity. Such effects would not be relevant for classification. In prenatal developmental toxicity studies, the administration of high doses is given in the guideline. The associated non-specific systemic toxicity often affects the maternal body weight. Therefore, published results of studies in rats and rabbits, where maternal weight gain during gestation was inhibited by restricted feeding, were examined regarding developmental effects. In summary, maternal feed restriction resulted in a reduction of fetal body weight that was sometimes accompanied by delayed ossification in both species. Considering their magnitude these effects could be interpreted as secondary non-specific (i.e. not caused by a developmental toxicant) effects. Based on the limited number of available publications in total no further consequences on prenatal development by maternal feed restriction were observed.


Assuntos
Fenômenos Fisiológicos da Nutrição Animal , Peso Fetal/fisiologia , Exposição Materna/efeitos adversos , Testes de Toxicidade/métodos , Redução de Peso/fisiologia , Anormalidades Induzidas por Medicamentos/etiologia , Anormalidades Induzidas por Medicamentos/fisiopatologia , Animais , Relação Dose-Resposta a Droga , Desenvolvimento Embrionário/efeitos dos fármacos , Feminino , Peso Fetal/efeitos dos fármacos , Masculino , Gravidez , Coelhos , Ratos , Aumento de Peso/fisiologia
3.
Environ Toxicol Pharmacol ; 35(2): 325-34, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23434523

RESUMO

The medicinal plants Aristolochia clematitis L. as well as Asarum europaeum L., representatives of the plant family Aristolochiaceae and mentioned in the German Homeopathic Pharmacopeia, contain aristolochic acid. We found that the mother tinctures of A. clematitis and A. europaeum inhibited DNA synthesis in human hepatoma HepG2 cells in a dose-dependent manner. One of the components of the plant extract, aristolochic acid I (AAI), is linked to the development of nephropathy and urothelial cancer in humans. Therefore, we also evaluated the cytotoxicity and genotoxicity of AAI in HepG2 cells. Cell proliferation was inhibited concentration-dependently by AAI using BrdU-ELISA and colony forming assay. AAI formed DNA adducts (measured by (32)P-postlabeling), induced chromosomal aberrations (micronuclei) and DNA strand breaks. DNA damage induced by AAI led to an arrest of cells in the S-phase which was associated with the increased expression of p53 and p21 proteins. The results are discussed under consideration of former studies.


Assuntos
Aristolochiaceae/química , Ácidos Aristolóquicos/toxicidade , Linhagem Celular Tumoral/efeitos dos fármacos , Linhagem Celular Tumoral/metabolismo , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Adutos de DNA/análise , Dano ao DNA/efeitos dos fármacos , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Homeopatia/métodos , Humanos , Testes de Mutagenicidade/métodos , NAD(P)H Desidrogenase (Quinona)/metabolismo , Extratos Vegetais/química , Extratos Vegetais/toxicidade , Pontos de Checagem da Fase S do Ciclo Celular/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA